May 22, 2003

News Release: Freezor(R) MAX Successfully Treats First Atrial Flutter Cases

CryoCath Technologies Inc., the world leader in cryotherapy products to treat cardiovascular disease, announced that its European-launched Freezor MAX catheter was used in seven recent Atrial Flutter cases at the Kerckhoff Klinik in Bad Nauheim, Germany by Dr. H. Pitschner. All seven cases resulted in acute successes. Atrial Flutter is the second most commonly ablated arrhythmia with an estimated 24,000 procedures each year in Europe alone.
The average procedure time for the cases was 1.7 hours and there were no complications or adverse events in any of the procedures and none of the patients reported experiencing any pain related to the ablation. This contrasts with radiofrequency (RF) ablation of Atrial Flutter where patients often report unacceptable levels of pain that require additional deep sedation or even general anesthesia. 'I have performed seven flutter ablation cases using Freezor MAX with acute success (bidirectional conduction block, measured after 30 minutes) in 100% of the cases,'said Dr. H. Pitschner, who becomes the first physician to perform cases with the Freezor MAX catheter. 'In contrast to RF ablation, none of the patients complained of pain. I am very

enthusiastic about these results and look forward to performing more cases and evaluating the long-term results.'In addition to being the first physician to clinically use Freezor MAX, Dr. Pitschner was a lead clinician on the Arctic Circler(TM) introduction in Europe. The Kerckhoff Klinik is a premier cardiology center heavily engaged in clinical arrhythmias, performing over 800 ablations per year.

The Freezor MAX catheter delivers more cooling power than Freezor(R) and Freezor(R) Xtra. It has a 30% larger luminen (9F versus 7F) allowing for more refrigerant to be delivered to the catheter tip and the tip itself is 33% larger (8mm versus 4 & 6 mm). By providing the optimal amount of refrigerant over a larger tip, Freezor MAX allows physicians to make larger, deeper lesions. This product is well suited to treat arrhythmias such as Atrial Flutter and prevalent left-sided arrhythmias, such as Ventricular Tachycardia (VT), where a more powerful lesion-making catheter is required due to anatomical considerations.

'By combining Freezor, which is positioned to treat AVNRT's, with Freezor MAX to treat Atrial Flutter, we now have two exciting products that we believe have the potential to be the first catheter of choice in the two most commonly ablated arrhythmias, accounting for more than two thirds of the total current European cardiac ablation market,'said Steven G. Arless, President and CEO of CryoCath.

Freezor MAX is in beta release to 5 centers in Europe until June 2003. Following this beta launch, the Company expects to broadly rollout the product across Europe leveraging the 50 plus base of centers that already have a CryoConsole installed. Freezor MAX is the fifth product CryoCath has commercialized in Europe.

About CryoCath

CryoCath -www.cryocath.com- is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S. and across Europe. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias and has research projects in ischemia and peripheral restenosis.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of CryoCath Technologies Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


Website: www.cryocath.com



CONTACT: TEL: (514) 694-1212 Steven G. Arless, President & CEO

CryoCath Technologies Inc.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

TEL: (416) 815-0700 ext. 231 Mike Polonsky, Investor Relations

FAX: (416) 815-0080

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.